Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Schizophr Bull. 2008 May;34(3):419-22. doi: 10.1093/schbul/sbn015. Epub 2008 Mar 28.

Paliperidone for treatment of schizophrenia.

Author information

  • 1Department of Psychiatry, University of North Carolina Hospitals, Chapel Hill, NC 27599-7160, USA. anussbau@unch.unc.edu

Abstract

In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound.

PMID:
18375569
[PubMed - indexed for MEDLINE]
PMCID:
PMC2632425
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1.
Fig. 2.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk